Local and systhemic immunotherapy for bladder cancer: from bench to bedside

被引:0
|
作者
Carballido, Joaquin A. [1 ]
Vazquez Alba, David [1 ]
Rodriguez Monsalve, Maria [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Serv & Catedra Urol, Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2020年 / 73卷 / 10期
关键词
Transitional cell bladder carcinom; Immunology and bladder cancer; Immunotherapy; Bacillus Calmette-Guerin; BCG Mechanism of action; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL-CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; T1 PAPILLARY CARCINOMA; TUMOR-NECROSIS-FACTOR; HIGH-RISK TA; INTRAVESICAL BCG; UROTHELIAL CARCINOMA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic approaches for treatment of urothelial transitional cell carcinoma based on immune system modulation, as well as the contribution of introvesical Bacillus de Calmette-Guerin (BCG) and the recent incorporation of checkpoint inhibitors had found irrefutable proofs of concept for the indication of antitumoral immunontherapy in such tumors. Its extension and development at the present time covers all the locations of the wide spectrum of presentation and evolution of these tumors. Nowadays, apart for the low grade non muscle-invasive tumors, we are facing an unpredictable development of antitumoral immunotherapy in bladder cancer not only as an option in the primary treatment, but also in other scenarios such as non-responders when it comes to BCG, or the situation of ineligibility for systemic chemotherapy indication. The main objective of this review article is trying to translate the current basic mechanisms involved in different phases of transitional cell carcinomas antitumoral response, regardless of whether they are muscle-invasive or not, and to establish the rationale for their therapeutic intravesical or systemic administration. The role of the interactions established between urothelial tumor cells and the cellular and molecular elements of the immune system of patients is described, incorporating the relevant and recent advances in immunobiology and the molecular characterization of these tumors that will undoubtedly introduce far-reaching modifications in therapeutic regimes that will contrast with the traditional options available. Investigational lines that are already active in the clinical research phase with BCG and, checkpoints inhibitors of the immune response are also analyzed, highlighting the need to find predictive response markers as a real option for treatments personalization. The approach to the knowledge of the individual reactivity of the immune system of each patient as a determining factor to achieve it is proposed.
引用
收藏
页码:879 / 894
页数:16
相关论文
共 50 条
  • [1] From Bench to Bedside: Immunotherapy for Prostate Cancer
    Tse, Brian Wan-Chi
    Jovanovic, Lidija
    Nelson, Colleen Coyne
    de Souza, Paul
    Power, Carl Andrew
    Russell, Pamela Joan
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [2] Translation of cancer immunotherapy from the bench to the bedside
    Guo, Qianyu
    Huang, Fan
    Goncalves, Christophe
    del Rincon, Sonia V.
    Miller, Wilson H., Jr.
    IMMUNOTHERAPY OF CANCER, 2019, 143 : 1 - 62
  • [3] Cancer photo-immunotherapy: from bench to bedside
    Wang, Miao
    Rao, Jie
    Wang, Meng
    Li, Xiaosong
    Liu, Kaili
    Naylor, Mark F.
    Nordquist, Robert E.
    Chen, Wei R.
    Zhou, Feifan
    THERANOSTICS, 2021, 11 (05): : 2218 - 2231
  • [4] From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
    Kunk, Paul R.
    Bauer, Todd W.
    Slingluff, Craig L.
    Rahma, Osama E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [5] Interleukin-10 in cancer immunotherapy: from bench to bedside
    Salkeni, Mohamad Adham
    Naing, Aung
    TRENDS IN CANCER, 2023, 9 (09): : 716 - 725
  • [6] Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
    Peyraud, Florent
    Guegan, Jean-Philippe
    Vanhersecke, Lucile
    Brunet, Maxime
    Teyssonneau, Diego
    Palmieri, Lola-Jade
    Bessede, Alban
    Italiano, Antoine
    MED, 2025, 6 (01):
  • [7] Predictive immune signatures for cancer immunotherapy - From bench to bedside
    de St Groth, Barbara Fazekas
    McGuire, Helen
    Kao, Steven
    McNeil, Catriona
    Hersey, Peter
    Boyer, Michael
    Vafaee, Fatemeh
    Choi, Clara
    Kwong, Chun-Ting Justin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 69 - 70
  • [8] mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
    Shariati, Alireza
    Khani, Pouria
    Nasri, Farzad
    Afkhami, Hamed
    Khezrpour, Arya
    Kamrani, Sina
    Shariati, Fatemeh
    Alavimanesh, Sajad
    Modarressi, Mohammad Hossein
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [9] From bench to bedside; A rationale for Immunotherapy in the adjuvant setting for Oesophageal cancer
    Donlon, Noel
    Davern, Maria
    Sheppard, Andrew
    Reynolds, John
    Lysaght, Joanne
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [10] Gene therapy and immunotherapy of advanced prostate cancer: from bench to bedside
    van Ophoven, A
    Patel, B
    Belldegrun, A
    Hinkel, A
    Senge, T
    AKTUELLE UROLOGIE, 1999, 30 (02) : 78 - 88